LAURA HENSLEY: Open Payments
NPI 1063958940 · SHERIDAN, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$587 in 32 payments from 14 companies in 2025. Trend: 2023 $404 · 2024 $509 · 2025 $587
Food & beverage: $587
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $113 |
| ABBVIE INC. | 6 | $107 |
| Janssen Biotech, Inc. | 4 | $75 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $36 |
| Novo Nordisk Inc | 2 | $34 |
| Lilly USA, LLC | 2 | $28 |
| Teleflex LLC | 1 | $26 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
Products named: TREMFYA, REXULTI, AIRSUPRA, BREZTRI, UBRELVY, XIFAXAN, VRAYLAR, UROLIFT.
Industry payments across AR — which companies pay providers there.
